Compounds for neutralising the effects of secreted pla2 iia
CA 2539065 C · Owner: Sheriff, Ahmed · Inventors: Vogt, Birgit; Sheriff, Ahmed
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A compound comprising at least a structural entity which binds secretory phospholipase A2 IIA (sPLA2 IIA) or parts of it and more preferably human sPLA2 IIA and which a.) blocks at least one or more sPLA2 IIA function on cell surfaces or in a solution, preferably blood or other body fluids or from tissues, most preferably in vivo, b.) and/or depletes sPLA2 IIA from a solution, preferably blood or other body fluids or from tissues most , preferably in vivo.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 22, 2004 and granted June 2, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 22, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 22, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.